- August 2, 2022
- Newsletter
- 617-430-5616
Menu
Brand Name :
Trandate
Synonyms :
labetalol
Class :
Antihypertensive and alpha/beta-blockers
Brand Name :
Trandate
Synonyms :
labetalol
Class :
Antihypertensive and alpha/beta-blockers
Dosage Forms & Strengths
Injectable solution
5mg/ml
Tablet
100mg
200mg
300mg
100
mg
Orally
every 12 hrs
initially; increased up to100 mg for 12hrs every 2-3 days Usual dosage range: 200-400 mg orally every 12hrs Do not exceed 2400 mg per day
20
mg
Intravenous (IV)
over 2 minutes initially
then 40-80 mg IV for every 10min
Do not exceed 300 mg per day
Dosage Forms & Strengths
Injectable solution
5mg/ml
Tablet
100mg
200mg
300mg
0.4 - 1
mg/kg
per hour by continuous IV infusion
do not exceed 3 mg/kg per hour
13
mg/kg
Orally
once a day
or divided for every 12hr
do not exceed 1200 mg per day
bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib
bradycardia-Causing Agents may enhance the bradycardic effect of ponesimod
may increase the bradycardic effect of bradycardia-causing agents
may have an increased bradycardic effect when combined with fingolimod
may have an increased bradycardic effect when combined with ponesimod
may have an increased bradycardic effect when combined with siponimod
may decrease the diagnostic effect when combined with benzylpenicilloyl polylysine
may have an increased hypertensive effect when combined with alpha1-blockers
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may decrease the bronchodilatory effect of beta2-agonists
may decrease the bronchodilatory effect of beta2-agonists
may decrease the bronchodilatory effect of beta2-agonists
may decrease the bronchodilatory effect of beta2-agonists
may decrease the bronchodilatory effect of beta2-agonists
may have an increased hypotensive effect when combined with calcium channel blockers
may have an increased hypotensive effect when combined with calcium channel blockers
may have an increased hypotensive effect when combined with calcium channel blockers
may have an increased hypotensive effect when combined with calcium channel blockers
may have an increased hypotensive effect when combined with calcium channel blockers
bradycardia causing agents increase the arrhythmia-causing effect of fexinidazole
may decrease the bronchodilatory effect
may increase the hypertensive effect of Monoamine Oxidase inhibitors
may increase the hypertensive effect of Monoamine Oxidase inhibitors
may decrease the vasoconstriction effects
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
may decrease the vasoconstricting effect when combined with alpha1-agonists
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may increase the vasoconstricting effect
may increase the vasoconstricting effect
may increase the vasoconstricting effect
may increase the vasoconstricting effect
may increase the vasoconstricting effect
may decrease the constriction effects of alpha-1 agonist
may decrease the constriction effects of alpha-1 agonist
hydrocodone/chlorpheniramine/pseudoephedrine
may decrease the vasoconstriction effects of alpha/beta agonists
may increase the bradycardia effect
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
bradycardia-causing agents increase the efficacy of ivabradine
may increase the hypotensive effect
may enhance the hypotensive effect of Alpha1-Blockers
may enhance the hypotensive effect of Alpha1-Blockers
may enhance the hypotensive effect of Alpha1-Blockers
may enhance the hypotensive effect of Alpha1-Blockers
may enhance the hypotensive effect of Alpha1-Blockers
may decrease the bronchodilatory effect of beta-blockers
may decrease the bronchodilatory effect of beta-blockers
may decrease the bronchodilatory effect of beta-blockers
may decrease the bronchodilatory effect of beta-blockers
may decrease the bronchodilatory effect of beta-blockers
acrivastine and pseudoephedrine
may increase the vasoconstrictive effect of alpha/beta agonists
may increase the bradycardic effect of bradycardia-causing agents
may increase the hypotensive effect of calcium channel blockers
may increase the hypotensive effect of calcium channel blockers
may enhance the orthostatic effect of beta blockers
may enhance the bradycardic effect of bradycardia-causing agents
may increase the effect of alpha1-blockers
may increase the effect of alpha1-blockers
may increase the effect of alpha1-blockers
may increase the effect of alpha1-blockers
may increase the effect of alpha1-blockers
may increase the effect of alpha1-blockers
may increase the hypotensive effect of blood pressure lowering agents
may decrease the antihypertensive effect when combined with beta-blockers
may decrease the antihypertensive effect when combined with beta-blockers
may decrease the antihypertensive effect when combined with beta-blockers
may decrease the antihypertensive effect when combined with beta-blockers
may decrease the antihypertensive effect when combined with beta-blockers
may decrease the vasoconstricting effect when combined with alpha-/beta-agonists
may decrease the vasoconstricting effect of Alpha-/Beta-Agonists
Adverse drug reactions:
Frequency defined
>10%
Tingling sensation of scalp
Nausea
Fatigue
Dizziness
Lightheadedness
1-10%
Absence of ejaculation
Elevated serum blood urea nitrogen (BUN)
Bronchospasm
Elevated serum creatinine
Dyspnea
Pruritus
Rash
Altered taste sense
Ventricular arrhythmia
Congestion of nasal sinus
Orthostatic hypotension
Paresthesia
Elevated liver enzymes
Diaphoresis
Edema
Frequency Not Defined
Bradycardia
Alopecia
Angioedema
Cholestatic jaundice
Depression
Pregnancy warnings:
AU TGA pregnancy category: C
US FDA pregnancy category: C
Breastfeeding warnings:
The release of the drug into the human breastmilk is known
Pregnancy Categories:
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first or later trimester.
Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits
Category X: Drugs listed in this category outweigh risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Patient Information Leaflet
Generic Name: labetalol
Pronounced: luh-BET-uh-lol
Why do we use labetalol ?
labetalol is an anti-hypertensive drug belonging to the subclass alpha/beta-blocker used to treat hypertension.
It mainly helps in decrease of high blood pressure and prevent risk of heart stroke, heart attacks and renal problems.